If such a drug could also interfere in a beneficial manner with other pathways contributing to AD – such as hyperphosphorylation of the cytoskeleton-associated protein Tau by glycogen synthase kinase 3 beta (GSK3beta)18 – this might be of high interest. This evidence concerns the gene GSK3B and Alzheimer disease.